TY - JOUR T1 - Shared Antigen-specific CD8<sup>+</sup> T cell Responses Against the SARS-COV-2 Spike Protein in HLA-A*02:01 COVID-19 Participants JF - medRxiv DO - 10.1101/2020.05.04.20085779 SP - 2020.05.04.20085779 AU - William Chour AU - Alexander M. Xu AU - Alphonsus H.C. Ng AU - Jongchan Choi AU - Jingyi Xie AU - Dan Yuan AU - Diana C. DeLucia AU - Rick A. Edmark AU - Lesley C. Jones AU - Thomas M. Schmitt AU - Mary E. Chaffee AU - Venkata R. Duvvuri AU - Kim M. Murray AU - Songming Peng AU - Julie Wallick AU - Heather A. Algren AU - William R. Berrington AU - D. Shane O’Mahony AU - John K. Lee AU - Philip D. Greenberg AU - Jason D. Goldman AU - James R. Heath Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20085779.abstract N2 - We report here on antigens from the SARS-CoV-2 virus spike protein, that when presented by Class I MHC, can lead to cytotoxic CD8+ T cell anti-viral responses in COVID-19 patients. We present a method in which the SARS-CoV-2 spike protein is converted into a library of peptide antigen-Major Histocompatibility Complexes (pMHCs) as single chain trimers that contain the peptide antigen, the MHC HLA allele subunit, and the β-2 microglobulin subunit. This library is used to detect the evolution of virus-specific T cell populations in four COVID-19 study participants two of which share one HLA allele, and the other two a second HLA allele, at two time points over the initial course of infection. HLA-matched participants exhibit similar virus-specific T cell populations, but very different time-trajectories of those populations. This strategy can be used to track those virus-specific T cell populations over the course of an infection, thus providing deep insight into the SARS-CoV-2 immune system trajectories observed in different COVID-19 patients.Competing Interest StatementJRH is a founder and board member of PACT Pharma, which is seeking to commercialize certain of the technologies described here.Funding StatementWe acknowledge the Parker Institute for Cancer Immunotherapy, the WA State Andy Hill CARE Foundation, the Wilke Foundation, the M.J. Murdock Charitable Trust, and the Swedish Foundation for generous support of this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the ISB data manager for release of data. ER -